{"denoms":[{"counts":[{"groupId":"BG000","value":"148"},{"groupId":"BG001","value":"160"},{"groupId":"BG002","value":"308"}],"units":"Participants"}],"groups":[{"description":"Patients receive cisplatin IV or carboplatin IV on day 1. Treatment repeats every 3 weeks for 4 courses in the absence of disease progression or unacceptable toxicity.\n\nCarboplatin: Given IV\n\nCisplatin: Given IV","id":"BG000","title":"Arm B (Cisplatin or Carboplatin)"},{"description":"Patients receive capecitabine PO BID on days 1-14. Treatment repeats every 3 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.\n\nCapecitabine: Given PO","id":"BG001","title":"Arm C (Capecitabine) (Open to Accrual 6/22/2016)"},{"description":"Total of all reporting groups","id":"BG002","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"27","upperLimit":"72","value":"52"},{"groupId":"BG001","lowerLimit":"26","upperLimit":"76","value":"52"},{"groupId":"BG002","lowerLimit":"26","upperLimit":"76","value":"52"}]}]}],"dispersionType":"FULL_RANGE","paramType":"MEDIAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"148"},{"groupId":"BG001","value":"160"},{"groupId":"BG002","value":"308"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"18"},{"groupId":"BG001","value":"15"},{"groupId":"BG002","value":"33"}],"title":"Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"123"},{"groupId":"BG001","value":"136"},{"groupId":"BG002","value":"259"}],"title":"Not Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"7"},{"groupId":"BG001","value":"9"},{"groupId":"BG002","value":"16"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Ethnicity (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}],"title":"American Indian or Alaska Native"},{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"7"},{"groupId":"BG002","value":"10"}],"title":"Asian"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}],"title":"Native Hawaiian or Other Pacific Islander"},{"measurements":[{"groupId":"BG000","value":"28"},{"groupId":"BG001","value":"31"},{"groupId":"BG002","value":"59"}],"title":"Black or African American"},{"measurements":[{"groupId":"BG000","value":"104"},{"groupId":"BG001","value":"115"},{"groupId":"BG002","value":"219"}],"title":"White"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}],"title":"More than one race"},{"measurements":[{"groupId":"BG000","value":"13"},{"groupId":"BG001","value":"7"},{"groupId":"BG002","value":"20"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race (NIH/OMB)","unitOfMeasure":"Participants"}],"populationDescription":"All patients who were concurrently randomized to arms B and C after 6/22/2016 and had basal-subtype disease, this was the primary analysis population for IDFS and other secondary efficacy endpoints (OS and RFS). Only patients included in the primary analysis are included in the analysis of baseline characteristics."}